The story of Viagra and its originator, copyright, presents a tangled picture for cautious investors. While the revolutionary drug initially produced enormous revenues , its patent has expired , leading to competing alternatives flooding the landscape . This decline in cost presents a significant hurdle for copyright and any fund considering a sign